NasdaqGS:INDVPharmaceuticals
Evaluating Indivior Pharmaceuticals (NasdaqGS:INDV) After New ASAM 2026 Data On Sublocade Effectiveness
Indivior Pharmaceuticals (INDV) drew fresh investor attention after presenting new real world data at the ASAM 2026 Annual Conference in San Diego on its monthly extended release buprenorphine treatment, SUBLOCADE, for opioid use disorder.
See our latest analysis for Indivior Pharmaceuticals.
Those ASAM data arrive at a time when Indivior Pharmaceuticals’ share price has shown an 18.43% 1 month share price return but remains slightly weaker year to date, while a very large 1 year total...